You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Faeth Therapeutics reported that PIKTOR plus paclitaxel achieved 33% confirmed ORR and 7.4-month preliminary median PFS in advanced endometrial cancer. 2 of 42 patients discontinued for treatment-related adverse events, and pivotal trial design is expected by 1H 2027.
Faeth Therapeutics reported Phase 2 results for PIKTOR plus paclitaxel in advanced endometrioid endometrial cancer: confirmed ORR was 33% (12 of 36), estimated median PFS was 7.4 months, and data support advancing PIKTOR into a Phase 3 registrational trial.
Faeth Therapeutics reported $174.8 million in cash, cash equivalents and marketable securities as of September 30, 2026 and $20.4 million net loss. FDA granted Fast Track designation to PIKTOR plus paclitaxel, while Phase 2 topline data are expected by year-end.
Faeth Therapeutics, Inc. reported a $206.6 million net loss for the nine months ended September 30, 2026, driven largely by $133.0 million of acquired IPR&D expense, while $174.8 million in cash and marketable securities supports PIKTOR trials through topline data.
Faeth Therapeutics, Inc. expanded its Board from six to seven directors on October 23, 2026, appointing Adam Schayowitz as a Class III director and granting him an option to purchase 25,000 common shares.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | 186.4M | as of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FTH
this stock
Faeth Therapeutics, Inc.
|
$259.21M | -6.0% | — | — | 10.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Faeth Therapeutics reported Phase 2 results for PIKTOR plus paclitaxel in advanced endometrioid endometrial cancer: confirmed ORR was 33% (12 of 36), estimated median PFS was 7.4 months, and data support advancing PIKTOR into a Phase 3 registrational trial.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FTH | -54.5% | -46.7% | -39.1% | -46.3% | -6.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -57.1% | -45.5% | -39.6% | -46.2% | -16.6% |
